VRDN•businesswire•
Viridian Therapeutics Prepares for Transformational 2026
Summary
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026. “Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress,” said Steve Mahoney, President and Chief Executive Officer of
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 6, 2026 by businesswire